In a historic 321 to 103 vote, the United States House of Representatives has passed a bill to allow banks to work with marijuana businesses that are legal under state law.
The measure now heads to the Senate, where its passage would send it to President Trump for consideration. Senate Banking Chairman Mike Crapo has said he wants to consider similar legislation in the coming months, notes Reuters, but it is not clear if the full Senate will vote on such a measure, analysts say.
“Some Republicans are wary of giving banks the green light to engage in marijuana business while it is still federally illegal”, says Reuters. “And some Democrats have said they would rather consider broader legislation around marijuana legalization or criminal justice reform rather than a targeted banking bill.”
The bill clarifies that proceeds from legitimate cannabis businesses would not be considered illegal, and directs federal regulators to write up rules for how they would supervise such banking activity.
Banks have thrown their weight behind the legislation, telling lawmakers they need clarity on whether they can do business with cannabis companies where it is legal at the state level despite the fact that marijuana remains illegal
Connecticut may soon be adding two new medical conditions that qualify under the state’s medical-marijuana program.
According to the Associated Press, a board of physicians voted Friday to recommend allowing doctors to prescribe the drug to adults with chronic pain that’s lasted at least six months and is associated with a specified underlying chronic condition. They’re also recommending adding Ehlers-Danlos syndrome, a group of disorders that affect connective tissues and can be painful.
Department of Consumer Protection Commissioner Michelle Seagull officially accepted the board’s recommendations, which now await additional reviews and ultimately a vote by the General Assembly’s Regulations Review Committee over the coming weeks.
Unfortunately, the physicians did not recommend adding night terrors and parasomnia to the list of eligible conditions.
As noted by the AP, currently, 40,000 patients are enrolled in Connecticut’s medical marijuana program.
Earlier this year House Bill 7371 to legalize marijuana for everyone 21 and older was passed out of its initial committee in a 10 to 8 vote. The measure would legalize and regulate commercial marijuana cultivation, processing, and sales in the state, while companion measures to tax cannabis and allow for expungements of past convictions are being considered by different committees.
According to a new study titled Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in multiple rodent models of nicotine dependence, the administration of the cannabis compound THCV (tetrahydrocannabivarin) reduces nicotine cravings and use in rodents.
The study was published by the British Journal of Pharmacology, as well as the U.S. National Institute of Health
For the study researchers at the Virginia Commonwealth University, the Beijing Institute of Pharmacology and Toxicology (China), and the University of Aberdeen (Scotland) assessed the influence of delta-8 THCV in seven different rodent models relevant to nicotine dependence. They reported that the compound significantly “attenuated intravenous nicotine self-administration, and both cue-induced and nicotine-induced relapse to nicotine-seeking behavior in rats [and] also significantly attenuated nicotine-induced conditioned place preference and nicotine withdrawal in mice.”
The study concludes by stating that “Δ8 -THCV may have therapeutic potential for the treatment of nicotine dependence. We also suggest that tetrahydrocannabivarins should be tested for possible anti-addiction efficacy in a broader range of preclinical animal models, against other addictive drugs, and eventually in humans.”
The study’s full abstract can be found below:
BACKGROUND AND PURPOSE:
Both types of cannabinoid receptors – CB1 and CB2 – regulate brain functions relating to addictive